Navigation Links
CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
Date:7/22/2008

with promising antidepressant properties and CeNeRx has collaborated with leading PET imaging experts at Brookhaven National Laboratory to produce comprehensive data on how plasma levels of Tyrima affect pathways in the brain," said K. Ranga Krishnan, MD, Professor and Chairman, Department of Psychiatry and Behavioral Sciences at Duke University Medical Center, and CeNeRx SAB member. "An agent such as Tyrima with proven MAOI activity in the CNS and a good tolerability profile could be a valuable new therapy for patients affected by depression. Successful completion of this PET imaging study, coupled with the positive results from the Phase I program, support progression of Tyrima into Phase II trials."

PET, or positron emission tomography, is a nuclear imaging technology that produces three-dimensional depictions of metabolic states in the human body, allowing researchers to view the path and amount of drug accumulation in study participants. The PET imaging study showed that Tyrima entered into and left the brain, achieved high plasma concentrations and exhibited a favorable pharmacokinetic half-life. Further results will be submitted for presentation at a future scientific meeting or for inclusion in a peer-reviewed medical publication.

CeNeRx has worldwide rights to develop and commercialize Tyrima. This compound, which could be the first RIMA antidepressant available in the U.S. market, has patent protection beyond 2027.

About CeNeRx BioPharma

CeNeRx (SEN-er-ex) is a privately held clinical stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, has completed Phase I development for the treatment of major depressive disorder. RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile. The company is also developing its
'/>"/>

SOURCE CeNeRx BioPharma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
4. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
5. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
6. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
9. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
10. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
11. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com announces ... available in its catalogue: ,, Boehringer ... http://www.reportlinker.com/p0168539/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile.html ,, Introduction ,, ... performance for Boehringer Ingelheim in the Rx ... portfolio and pipeline analysis and assessment of ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The Future ... to 2015, Competitive Benchmarking, Product Pipeline ... http://www.reportlinker.com/p0168102/The-Future-of-HIV-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, Summary ... latest research "The Future of HIV ...
(Date:12/15/2009)... Belgium, Dec. 15 Ghent University Hospital ... world to pioneer radiotherapy treatments using arc therapy, ... and efficient RapidArc radiotherapy technology from Varian Medical ... patient was treated in just 75 seconds, over ... treatments. ,, "This treatment would have taken more ...
Breaking Medicine Technology:Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 2European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 3New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 1New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 2New Research Shows Over use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist initiated Physician Intervention 6226 3Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 1Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 2Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 3Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology 6223 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 1Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 2Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 3Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non Constipating Irritable Bowel Syndrome 6220 5
... Nov. 24 A new cancer treatment is,realizing ... treatment, a patient,s large, stage 4 tumor was ... of treatment, it no longer could be definitely,identified ... to nine months,after diagnosis. NeoPlas Innovation,s combination of ...
... moderate to severe acute pain and their health-care providers will ... Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD), announced that the ... for the relief of moderate to severe acute pain in ... , Tapentadol is a new centrally acting ...
Other Medicine Technology:New Cancer Treatment Shrinks Pancreatic Tumor 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 3FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 4FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 6
(Date:12/15/2009)... suicide goes up within a week of getting ... News) -- Emotional stress can put newly diagnosed ... events and suicide, a new study has found. ... diagnosed with prostate cancer between 1961 and 2004. ... cardiovascular event within a year of cancer diagnosis ...
(Date:12/15/2009)... R.I., Dec. 15 Mergers and acquisitions ... expand their reach globally or complete a product ... the integration of safety programs. ,, A new ... Best Practices in a Hearing Conservation Program: US ... Airways and America West led the newly formed ...
(Date:12/15/2009)... by the Technology-based Learning SIG of ASTD,s Atlanta ... eLearning designs. This year nominees, eleven (11) ... The Venza Group entry, a highly engaging modular ... selected as the winner of the "Greater Than ... panel of distinguished judges. While announcing the ...
(Date:12/15/2009)... Inhibiting fatty acid synthesis in brain cancer cells may ... of deadly glioblastomas that are driven by amplified signaling ... a first-of-its-kind study by researchers at UCLA,s Jonsson Comprehensive ... acids for the formation of new membranes. The fatty ... cancer cells, and may be important for regulating cell ...
(Date:12/15/2009)... scientists have found the first potential immunological clue of ... the pandemic H1N1 virus. , The study analyzed ... 15 outpatients and 15 control subjects in 10 Spanish ... August 2009. Researchers from the Hospital Clinico Universitario de ... high levels of a molecule called interleukin 17 in ...
Breaking Medicine News(10 mins):Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 2Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 3Health News:New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways 4Health News:The Venza Group Received Top Honors at the American Society of Training & Development (ASTD) eLearning Excellence Awards Ceremony Held on December 10, 2009 2Health News:Targeting brain cancer cell metabolism may provide new treatment 2Health News:Targeting brain cancer cell metabolism may provide new treatment 3Health News:First immunological clue to why some H1N1 patients get very ill or die 2
... According to a Norwegian study of 1656 subjects over an ... in the workplace is linked to a significant increase in ... and its surroundings were enrolled in 1985 and asked about ... asthma. ,Then, after 5 years 1656 of the ...
... type 2 diabetes. According to a new survey, they showed ... been selected for a pancreas transplant.// Obesity is a strong ... the immune system destroys the insulin-producing cells of the pancreas. ... insulin, usually in the middle age. ,Pancreas transplantation, ...
... preserve their voice box. Treatment for laryngeal cancer often includes ... to learn to speak through an opening made in the ... that has a drastic impact on the quality of that ... been looking into other treatment approaches for laryngeal cancer. In ...
... is a slow killer that ticks away in one out ... These were among the facts and figures trotted out on ... Day. Gathered in front of the Victoria Statue, Cubbon Park, ... the City Police, and the Bangalore Metropolitan Transport Corporation (BMTC). ...
... Stress on human life has been increasing day by day.It ... a more healthy and peaceful life style.//This article is ... get angry for trivial things which does not concern us.But ... life threatning cardiac arrest in patients with heart disease by ...
... there's a firm connection between viral infection and pre-cancerous lesions ... human papillomavirus (HPV)// may increase the risk of cervical cancer. ... history of abnormal cervical cell growth were followed for ten ... another two years later. Those who were free of HPV ...
Other Medicine News:
The Escape Basket offers a side-by-side approach, unique to the market, for using a nitinol basket and holmium laser fiber together-providing physician control and independent manipulation of both th...
Simple, Effective Laparoscopic Irrigation Pumps from the Market Leader...
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
... is a minimally invasive, highly effective surgical ... incontinence. GYNECARE TVT is positioned close to ... and when needed, TVT provides tension-free support ... The procedure takes approximately 20 to 30 ...
Medicine Products: